Healthcare Social Network. Share Knowledge, Be Discovered, Find Opportunities. Join Now
Both Bydureon and Victoza are considered analogs of the hormone GLP-1. GLP-1 increases insulin secretion, increases B-cell growth, slows absorption of glucose from the gut, and may decrease food intake. Neither medication should be given to patients with type 1 diabetes, nor are they recommended as a first-line of therapy for type 2 diabetics. Patients with diabetic ketoacidosis (DKA) and pancreatitis should not use these medications. In addition, insulin should not be used along with Bydureon or Victoza.
Efficacy of Bydureon versus Byetta
In comparison to Byetta, Bydureon is administered once-weekly, as opposed to once-daily. Bydureon, the extended release form of Byetta (exenatide) was more effective than Byetta in a 24-week clinical study. The 24-week study concluded that Bydureon 2 mg injected once weekly reduced HbA1c by an average of 1.6 % while Byetta reduced HbA1c by 0.9%. Weight loss was also slightly more with Bydureon compared to Byetta. The average weight loss was 2.3 kg with Bydureon compared to 1.4 kg with Byetta.
Efficacy of Victoza versus Byetta
In a 26 week study comparing effects of Victoza and Byetta, 54% of patients that received Victoza achieved an HbA1c goal of less than 7% compared to 43% of patients that received Byetta. Weight loss was comparable at around 3 kg in both groups. Changes in fasting glucose were -29 mg/dl with Victoza and -11 mg/dl with Byetta.
Efficacy of Victoza versus Bydureon
In a 26 week clinical trial comparing Bydureon (2 mg weekly) to Victoza (1.8 mg daily), HbA1c reduction and side effects of the two drugs were studied. The average baseline HbA1c was 8.5%. Subjects achieved an average decrease in HbA1c of about 1.3% with Bydureon and about 1.5% with Victoza. 60.2% of subjects treated with Vicotoza achieved HbA1c <7% versus 52.3% of Bydureon treated subjects. Gastrointestinal side effects occurred more frequently among patients taking Victoza (nausea 20%, vomiting 11%, diarrhea 13%) compared to subjects taking Bydureon (nausea 9%, vomiting 4%, and diarrhea 6%). Weight loss was 3.6 kg in the Vicotza group and 2.7 kg in the Bydureon group.
How are Bydureon and Victoza administered?
Bydureon has a more convenient dosing schedule because it is administered once weekly. After Bydureon is injected it stays as a reservoir under the skin until the medication is slowly distributed throughout the body. While Victoza comes in a preset pen, Bydureon is supplied as a powder that is mixed and then immediately injected under the skin. For patients uncomfortable with needles, the needle size is smaller for Victoza compared to Bydureon.
For more prescribing information, including price and prescription cost assistance for Byetta, Bydureon, and Vicotza read the following articles.
Bydureon may be preferred over Victoza for patients who are noncompliant or do not like daily injections. In addition, Bydureon may be an alternative option if patients experience excessive stomach side effects from Victoza, (like nausea, vomiting, diarrhea, constipation). If a patient is having trouble reducing HbA1c or wishes to lose more weight, Victoza has an edge over Bydureon. According to recent studies patients were able to lose slightly more weight and reduce HbA1c more with Victoza compared to Bydureon. Ease of administration may be important to some patients. Bydureon comes in a powder form that is mixed with liquid then injected with a larger size needle than Victoza. Victoza comes in a ready-to-use pre-filled multi-dose pen (Victoza pen).
Buse, John. Liraglutide Once a Day versus Exenatide Twice a Day for Type 2 Diabetes: A 26-week Randomised, Parallel-group, Multinational, Open-label Trial (LEAD-6).The Lancet. N.p., 08 June 2009. Web. 10 June 2012.
Victoza Prescribing Information. Novo Nordisk Inc, 06 Apr. 2012. Web. 06 June 2012.
Bydureon Prescribing Information. Amylin Pharmaceuticals, Jan. 2012. Web. 06 June 2012.
Buse, John. Efficacy and safety of exenatide once weekly versus liraglutide in subjects with type 2 diabetes (Duration-6): a randomized, open-label study. Diabetologica. 2011; 54 (Suppl 1); S38. Abstract 75
Comment on this article or post an article by joining the RxEconsult community.
Please Share on Your Social Networks
This medication summary is for information only and is not a substitute for medical advice, diagnosis or treatment provided by a qualified health care provider.
More Articles by Nageen Mohamadi, PharmD